This work was conducted at The Department of Nuclear Medicine, Rikshospitalet-Radiumhospitalet Health Entreprise, University of Oslo, Norway.
Breath Actuated Device Improves Delivery to Target Sites Beyond the Nasal Valve†
Version of Record online: 2 JAN 2009
Copyright © 2006 The Triological Society
Volume 116, Issue 3, pages 466–472, March 2006
How to Cite
Djupesland, P. G., Skretting, A., Winderen, M. and Holand, T. (2006), Breath Actuated Device Improves Delivery to Target Sites Beyond the Nasal Valve. The Laryngoscope, 116: 466–472. doi: 10.1097/01.MLG.0000199741.08517.99
This study has been supported by the Norwegian Regional Industrial Development Fund, The Norwegian Research Council, and OptiNose AS.
Presented in part at the Nasal Drug Delivery conference in London, United Kingdom, April, 7, 2005, organized by Management Forum, and at the Nasal Drug Delivery Meeting, Washington, DC, U.S.A., July 26, 2005, organized by Pharmaceutical Education Associates.
Two of the authors, P. G. Djupesland and T. Holand are founders and shareholders of OptiNose AS, a commercial company developing nasal delivery devices.
A. Skretting and M. Winderen have no commercial interests in OptiNose AS.
- Issue online: 2 JAN 2009
- Version of Record online: 2 JAN 2009
- Manuscript Accepted: 30 NOV 2005
- Middle meatus;
- nasal delivery;
- nasal valve;
Objectives: The objective was to compare nasal deposition patterns achieved with a conventional hand actuated spray pump and a novel breath actuated bidirectional prototype device housing the same spray pump (OptiMist™, OptiNose AS, Oslo, Norway).
Study Design and Methods: The bidirectional delivery device exploits the posterior connection between the nasal passages persisting when the velum automatically closes during oral exhalation. The deposition and clearance patterns achieved with the two devices were compared in nine healthy subjects by scintigraphy after administration of 99mTc-aerosols.
Results: Compared with traditional spray pump delivery, the OptiMist device provided significantly (P < .004) larger initial and cumulative deposition (area under the deposition vs. time curve) in the upper posterior segment of the nasal passage, housing the sinus ostia and the olfactory region, and significantly lower deposition (P < .004) in the anterior segment, lined by nonciliated squamous epithelium. Furthermore, intersubject reproducibility of the initial and cumulative deposition was higher for the OptiMist™ device both in the upper posterior segment and the entire nose.
Conclusions: Compared with a spray pump, the novel breath actuated bidirectional device provides significantly larger deposition in the clinically important regions beyond the nasal valve and reduced anterior deposition. These striking differences provide new opportunities for improved therapy of chronic rhinosinusitis and polyposis as well as extended use of the nose for delivery of drugs from the nose into the brain.